Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

91 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Effects of esketamine nasal spray on depressive symptom severity in adults with treatment-resistant depression and associations between the Montgomery-Åsberg Depression Rating Scale and the 9-item Patient Health Questionnaire.
Kern Sliwa J, Naranjo RR Jr, Turkoz I, Petrillo MP, Cabrera P, Trivedi M. Kern Sliwa J, et al. Among authors: turkoz i. CNS Spectr. 2024 Apr 1:1-11. doi: 10.1017/S1092852924000105. Online ahead of print. CNS Spectr. 2024. PMID: 38557430
Relapse Rates With Paliperidone Palmitate in Adult Patients With Schizophrenia: Results for the 6-Month Formulation From an Open-label Extension Study Compared to Real-World Data for the 1-Month and 3-Month Formulations.
Turkoz I, Daskiran M, Siddiqui U, Knight RK, Johnston KL, Correll CU. Turkoz I, et al. Int J Neuropsychopharmacol. 2024 Feb 1;27(2):pyad067. doi: 10.1093/ijnp/pyad067. Int J Neuropsychopharmacol. 2024. PMID: 38300235 Free PMC article. Clinical Trial.
Does COVID-19 Cause Non-Dıpper Hypertension?
Sivri F, Türköz I, Şencan M, İçen YK, Aksoy F, Ceyhan BÖ. Sivri F, et al. Among authors: turkoz i. Angiology. 2023 Oct 20:33197231209584. doi: 10.1177/00033197231209584. Online ahead of print. Angiology. 2023. PMID: 37864346
Efficacy and Safety of Esketamine Nasal Spray in Patients with Treatment-Resistant Depression Who Completed a Second Induction Period: Analysis of the Ongoing SUSTAIN-3 Study.
Castro M, Wilkinson ST, Al Jurdi RK, Petrillo MP, Zaki N, Borentain S, Fu DJ, Turkoz I, Sun L, Brown B, Cabrera P. Castro M, et al. Among authors: turkoz i. CNS Drugs. 2023 Aug;37(8):715-723. doi: 10.1007/s40263-023-01026-3. Epub 2023 Aug 9. CNS Drugs. 2023. PMID: 37558912 Free PMC article.
Long-Term Efficacy and Safety of Paliperidone 6-Month Formulation: An Open-Label 2-Year Extension of a 1-Year Double-Blind Study in Adult Participants With Schizophrenia.
Najarian D, Turkoz I, Knight RK, Galderisi S, Lamaison HF, Zalitacz P, Aravind S, Richarz U. Najarian D, et al. Among authors: turkoz i. Int J Neuropsychopharmacol. 2023 Aug 29;26(8):537-544. doi: 10.1093/ijnp/pyad028. Int J Neuropsychopharmacol. 2023. PMID: 37480362 Free PMC article. Clinical Trial.
Predictors of response and remission in patients with treatment-resistant depression: A post hoc pooled analysis of two acute trials of esketamine nasal spray.
Turkoz I, Nelson JC, Wilkinson ST, Borentain S, Macaluso M, Trivedi MH, Williamson D, Sheehan JJ, Salvadore G, Singh J, Daly E. Turkoz I, et al. Psychiatry Res. 2023 May;323:115165. doi: 10.1016/j.psychres.2023.115165. Epub 2023 Mar 16. Psychiatry Res. 2023. PMID: 37019044 Free article. Clinical Trial.
91 results